Artios is an England-based biotechnology company that researches and develops DNA damage response therapies for the treatment of cancer... Read more
Artios is an England-based biotechnology company that researches and develops DNA damage response therapies for the treatment of cancer... Read more
News
Sep 28, 2021
MarketScreener
Artios Pharma: Artios Doses First Patient in Phase 1/2a Study of Pol? Inhibitor ART4215
Aug 09, 2021
Cambridge Network
Artios Pharma: Artios announces 110 Million Series C financing
Aug 06, 2021
Global Legal Chronicle
Artios Pharma: Artios Pharma Limited's US$153 Million Series C Financing
Jul 29, 2021
Global University Venturing
Artios Pharma: Investors assist Artios in $153m series C - University Venturing: News, Data, and Events - Global University Venturing
Jul 29, 2021
Business Weekly
Artios Pharma: US investors lead $153m round for Artios Pharma
Jul 27, 2021
Venture Capital Journal
Artios Pharma: Artios Pharma snaps up $84m Series B
Jul 27, 2021
FierceBiotech
Artios Pharma: Artios raises $153M to fund DNA damage repair clinical trials
Jul 26, 2021
BioSpace
Artios Pharma: Artios Adds $153M to the Bank Amidst a Year of Major Collab Deals
Jun 18, 2021
MarketScreener
Artios Pharma Ltd.: IP : Artios Pharma Ltd - Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Pol Polymerase Inhibitor in Nature Communications
Apr 07, 2021
The Pharma Letter
Artios Pharma Ltd.: Artios links up with Novartis on DDR cancer therapies
Artios Pharma Competitors
1
2
3
4
5
6
7
8
9
10